PMVP · NASDAQ · Biotechnology

PMV Pharmaceuticals

Develops a precision-oncology therapy for cancers with TP53 Y220C mutations.

$0.9899
Pre-market−0.22 (−18.19%)
At close$1.21(−0.82%)

Something off on this page? Send us feedback.

Next report
Nov 11, 2026
estimated · in 71 days
EPS estimate
−$0.34
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.34−$0.41−$0.40−$0.34−$0.34−$0.34−$0.34Pending
Estimate−$0.37−$0.39−$0.40−$0.40−$0.41−$0.39−$0.39−$0.34
Surprise+8.1%−5.1%0.0%+15.0%+17.1%+12.3%+12.3%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.34
Aug 2026−$0.39−$0.34+12.3%
Aug 2026−$0.39−$0.34+12.3%
May 2026−$0.41−$0.34+17.1%
Mar 2026−$0.40−$0.34+15.0%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Sep 2020
Jun 2020
Dec 2019
Sep 2019
Jun 2019
Mar 2019
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 11, 2026−$0.34
Aug 14, 2026−$0.39−$0.34+12.3%+3.3%
Aug 13, 2026−$0.39−$0.34+12.3%−3.2%
May 12, 2026−$0.41−$0.34+17.1%−9.2%
Mar 6, 2026−$0.40−$0.34+15.0%−0.6%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
Nov 12, 2025
Aug 7, 2025
May 9, 2025
Mar 3, 2025
Nov 7, 2024
Aug 8, 2024
May 9, 2024
Feb 29, 2024
Nov 9, 2023
Aug 9, 2023
May 10, 2023
Mar 1, 2023
Nov 8, 2022
Aug 9, 2022
May 10, 2022
Mar 1, 2022
Nov 12, 2021
Aug 13, 2021
May 14, 2021
Mar 3, 2021
Nov 13, 2020
Sep 25, 2020
Jun 30, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019